ReviewCancer discovery2012
Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer.
Review in Cancer discovery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- A Feasibility Study Showing [Molecular imaging and biology · 2016Trial
- The Relationship Between PSA and Total Testosterone Levels in Men With Prostate Cancer.The journal of sexual medicine · 2022Article
- Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges.Nuclear medicine and molecular imaging · 2017Review
- Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.Molecular cancer research : MCR · 2017Article
- Noninvasive Measurement of mTORC1 Signaling withClinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Article
- Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.International journal of urology : official journal of the Japanese Urological Association · 2016Review
- Synthesis and Characterization of (89)Zr-Labeled Ultrasmall Nanoparticles.Molecular pharmaceutics · 2016Article
- Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins.Molecular pharmaceutics · 2016Article
- Imaging active urokinase plasminogen activator in prostate cancer.Cancer research · 2015Article
- Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014Article
- Imaging Hepatocellular Carcinoma WithMolecular imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
unlabelledAs parallel advances in cancer biology and drug development continue to elevate the role of targeted therapies in oncology, the need for imaging biomarkers that systematically measure the biology associated with therapeutic intervention has become more urgent. Although the molecular imaging community has a commitment to develop technologies to this end, few investigational radiotracers directly measure the biology of common oncogenic signaling pathways often addressed by targeted therapies. Visible progress has been achieved with a handful of radiotracers rationally designed to intercalate the pathobiology of prostate cancer, a molecularly heterogeneous disease nevertheless broadly defined by a fairly small repertoire of recurrent oncogenic lesions. SIGNIFICANCE: That variable treatment responses or emergent resistance phenotypes are often documented in humans argues strongly for diagnostic technologies that can be realistically applied posttherapy to capture the dynamic patterns of disease response. The purpose of this review is to describe a collection of radiotracers developed to measure the pathobiology of prostate cancer for improved treatment monitoring, placing particular emphasis on the biologic rationale for their preparation. A chronologic description of radiotracer development programs is outlined, primarily to stress how an ongoing dialectic between earlier and more contemporary imaging technologies has accelerated discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.